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Background: Colorectal cancer (CRC) is one of the most common malignancies, 
and the only reliable treatment option for cure is surgery.  
 
Method: Quantitative real-time polymerase chain reaction was used to analyze the 
gene expression of the enzyme thymidine phosphorylase (TP), which was related 
to prognostic factors (paper I, n=254), evaluated as a predictive factor (paper III, 
n=125), and assessed by change of treatment (paper II, n=28). Data from the 
Swedish Colorectal Cancer Registry were retrieved and analyzed in order to assess 
adherence to present clinical guidelines (n=34,000). 
 
Results: In stage III CRC, TP analyzed in tumor tissue correlated with lymph 
node staging, with higher expression levels relating to a greater number of positive 
nodes and a worse N-stage. Higher TP expression was also associated with a 
worse histological tumor grade. Rectal cancer exhibited significantly higher TP 
expression in mucosa and tumor tissue compared to colon cancer. There was a 
significant increase of TP gene expression when comparing rectal cancer biopsies 
before and after radiotherapy. In addition, a decrease in TP levels was noted after 
chemotherapy. In patients with metastatic CRC, time to progression was 
significantly longer in patients with high TP expression, but there was no 
correlation to tumor response rate or palliative survival.  
The factors associated with adherence to guideline treatment in colon cancer stage 
III patients were lower age, less comorbidity, worse N-stage, and presence of a 
multidisciplinary team conference. One-third of the patients started their adjuvant 
chemotherapy more than eight weeks after surgery. 
 
Conclusion: TP may be useful in prognostic and predictive situations. TP is 
affected by radiotherapy, which might be used in clinical settings. However, there 
are conflicting results, and TP and the methods of analyzing TP need to be 
evaluated further in larger studies. The adherence to guideline treatment in colon 
cancer stage III is acceptable in younger and healthier patients. In addition, there is 
scope for shortening the waiting time until the start of chemotherapy. 
 
Keywords: colorectal neoplasms, thymidine phosphorylase, chemotherapy, 
adjuvant, biological markers, prognosis, practice guidelines, radiotherapy 
 
 
ISBN: 978-91-628-9086-5  http://hdl.handle.net/2077/35950 
  ISBN: 978-91-628-9092-6 
 
